What the PCOS Rename Means for Primary Care
Last Updated: May 2026
Medically reviewed by Dr. Kelli Peiffer, owner and founder of West Side Concierge Medicine
On May 12, 2026, a paper published in The Lancet formally renamed polycystic ovary syndrome. The condition affecting one in eight women, more than 170 million people worldwide, is now polyendocrine metabolic ovarian syndrome, or PMOS. The rename followed 14 years of global collaboration, more than 14,000 survey responses from patients and clinicians across every world region, and consensus across 56 patient and professional organizations.
For anyone who has spent time managing this condition in a primary care setting, the clinical logic behind the change is not surprising. What is worth sitting with is how much the old name cost, and what the new one demands.
A Name That Pointed in the Wrong Direction
The term polycystic ovary syndrome implied pathological ovarian cysts. Research confirms there is no increase in abnormal ovarian cysts in women with the condition. What does define it is a complex, multisystem network of endocrine and metabolic dysfunction that the name never captured and that the clinical system, following the name's lead, frequently failed to address.
The consequences were measurable. Up to 70% of affected individuals remained undiagnosed. Those who did receive a diagnosis frequently reported dissatisfaction with their care. Fragmented management across multiple specialists was common, with each provider treating one feature of the condition in isolation from the others. Research funding, clinical guidelines, and medical education all organized themselves around an ovarian and reproductive framing that left the metabolic, psychological, and cardiovascular dimensions of the condition consistently undertreated.
The Lancet paper is direct about this. The inaccurate name contributed to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing. When a condition is categorized as a gynecologic problem, everything from how medical students encounter it to how health systems code it follows that framing. In this case, the framing was wrong, and patients absorbed the cost of that error for decades.
What the New Name Reflects Clinically
Each term in polyendocrine metabolic ovarian syndrome carries clinical weight that the old name obscured.
Polyendocrine reflects that PMOS involves multiple interacting hormonal systems. Hyperandrogenism is a defining diagnostic feature, with elevated ovarian and often adrenal androgens contributing to hirsutism, acne, alopecia, and metabolic dysfunction. Central neuroendocrine abnormalities, including increased gonadotropin-releasing hormone pulsatility and consequent elevations in luteinizing hormone, drive excessive ovarian androgen production. These neuroendocrine disruptions are not primarily ovarian in origin. The ovaries are downstream targets of a dysregulated system, even as their dysfunction is real and central to the condition's presentation.
Metabolic reflects what the condition does systemically and what it demands clinically. Insulin resistance is present in the majority of affected individuals, estimated at 50 to 70% by standard clinical measures and up to 75 to 95% in clamp-based studies, including a substantial proportion of lean women with PMOS. It amplifies androgen secretion, disrupts steroidogenesis, and drives the cardiometabolic complications that have been systematically under-screened in this population. Impaired glucose tolerance, type 2 diabetes, dyslipidemia, hypertension, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease risk are all documented features. Evidence from predominantly premenopausal women shows that odds ratios for composite cardiovascular disease, myocardial infarction, and stroke are meaningfully elevated in those with PMOS compared to those without. These are not incidental findings. They are features of the condition that belong on the problem list and in the management plan.
Ovarian remains because ovarian dysfunction is real and central. Neuroendocrine abnormalities disrupt steroidogenesis and impair follicular maturation. Ovulatory dysfunction, menstrual irregularity, and infertility are direct clinical consequences. But the ovaries are one part of a multisystem condition, not the organizing principle of it.
The psychological dimension warrants its own mention. Depression, anxiety, disordered eating, and poor quality of life are documented features of PMOS, understood now as downstream consequences of the endocrine disruption at the condition's core rather than separate comorbidities to be referred out.
What This Means for Primary Care Practice
The rename does not change diagnostic criteria. The three established criteria, oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries on ultrasound or elevated anti-Müllerian hormone, remain in place. What changes is the clinical frame through which the condition is managed after diagnosis.
A patient who receives a PMOS diagnosis is not presenting with a fertility problem that happens to have some metabolic features. She is presenting with a chronic, multisystem hormonal and metabolic condition that requires longitudinal management across several domains simultaneously. Hormones, metabolic function, cardiovascular risk, psychological wellbeing, and skin and hair changes are all features of the same condition. Managing one or two of them is not comprehensive care for PMOS.
Basma Faris, MD, CCMS, obstetrician-gynecologist and nutritionist at the Icahn School of Medicine at Mount Sinai and a past HERmedicine faculty member, has emphasized that patients with PMOS should be monitored closely for insulin resistance and cardiovascular risk factors and counseled on nutrition and lifestyle interventions as part of routine management. She has also noted the elevated endometrial cancer risk associated with the condition, an often-overlooked consequence of chronic ovulatory dysfunction that warrants explicit patient education and clinical vigilance. These are not peripheral concerns. They are features of the condition that belong on the problem list from the point of diagnosis forward.
That clinical reality has always been true. What the rename does is make it harder to ignore. When the condition is named after one organ, the clinical system can, and frequently does, treat it as one organ's problem. When the condition is named for its actual pathophysiology, the standard of care has to follow.
There is also a population worth keeping in mind that the reproductive framing has historically obscured. PMOS does not simply resolve at menopause, though the picture is more complicated than the reproductive framing ever allowed for. Hyperandrogenism persists after menopause, and larger cohort studies support a continuing elevated risk of coronary events including myocardial infarction in older women with a PCOS history. The extent to which cardiometabolic risk is driven by obesity as a confounder versus the underlying condition remains an active area of study, with some evidence that BMI-matched comparisons narrow the gap considerably. What is clear is that perimenopausal and postmenopausal women with a historical PCOS diagnosis are carrying forward clinical history that has frequently never been addressed comprehensively during their reproductive years. The rename offers an entry point for that conversation that the old framing made easy to defer.
A Three-Year Transition and What Comes Next
A managed three-year transition period is underway. Full integration into the International Guidelines is planned for the 2028 update, which is already used in 195 countries. In the interim, both names will circulate in clinical settings, insurance documentation, and patient records. The implementation strategy includes integration into electronic health records, engagement with international disease classification bodies including WHO for ICD coding updates, and alignment with research funders and journal processes.
For primary care providers, the practical implication in the near term is that patients are going to come in having read about the rename and wanting to understand what it means for their care. That is an opportunity. A patient who has spent years feeling that her diagnosis never quite explained what she was experiencing is now being told by the international medical community that she was right. The clinical conversation that follows that moment is one that primary care is positioned to lead, if the practice structure allows for it.
As Dr. Faris has framed it, the goal of this reclassification is to redirect clinical thinking toward PMOS as a long-term chronic condition rather than a problem defined by its menstrual symptoms. That reframe has implications for how providers screen, how they monitor, and how they structure ongoing care relationships with this patient population. The condition formerly known as PCOS has always required more time, more clinical breadth, and more longitudinal continuity than the standard primary care model reliably provides. The rename does not change that. It does make the argument for a different kind of practice model harder to dismiss.
Additional Resources
The Cochrane Database of Systematic Reviews. 2019. Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH.SR
Journal of the American Heart Association. 2024. Tay CT, Mousa A, Vyas A, et al.SR
Clinical Endocrinology. 2025. Elhassan YS, Hawley JM, Cussen L, et al.NewGuideline
Hepatology. 2023. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.Guideline
5. Polycystic Ovary Syndrome and Endometrial Cancer Risk: Results From a Nationwide Cohort Study.
American Journal of Epidemiology. 2024. Frandsen CLB, Gottschau M, Nøhr B, et al.
6. Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome.
The Journal of Clinical Endocrinology and Metabolism. 2024. Pace L, Markovic D, Buyalos R, Bril F, Azziz R.SR
The New England Journal of Medicine. 2016. McCartney CR, Marshall JC.Review
8. Risk of Endometrial Cancer in Patients With Polycystic Ovarian Syndrome: A Meta‑analysis.
Oncology Letters. 2023. Johnson JE, Daley D, Tarta C, Stanciu PI.
Human Reproduction. 2023. Teede HJ, Tay CT, Laven J, et al.Guideline
Fertility and Sterility. 2019. Kim JJ, Hwang KR, Oh SH, et al.
Clinical Endocrinology. 2019. Li W, Chen Q, Xie Y, et al.
12. The impact of ageing and menopause in women with polycystic ovary syndrome.
Clinical Endocrinology. 2022. Helvaci N, Yildiz BO.Review
13. Association of Polycystic Ovary Syndrome With Atherosclerotic Cardiovascular Disease Events.
Fertility and Sterility. 2025. Lee I, Dokras A, Alur-Gupta S.NewReview
14. Consensus on Women's Health Aspects of Polycystic Ovary Syndrome (PCOS): The Amsterdam ESHRE/
ASRM-Sponsored 3rd PCOS Consensus Workshop Group.
Fertility and Sterility. 2012. Fauser BC, Tarlatzis BC, Rebar RW, et al.Guideline
